Alterity Therapeutics Limited
Alterity Therapeutics Limited (ATHE): 2 pipeline candidates · 1 upcoming catalyst · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
D/E 0.09 · 0% dilution
Lead: Approved
2 candidates
1 upcoming, next in ~5189d
N/A
A transparent, data-derived signal for Alterity Therapeutics Limitedacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$93.2M
Cash
$33.2M
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (2 candidates)
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$424K
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 58,382 | $203K |
| greenleaf trust | 32,000 | $111K |
| citadel advisors llc | 20,077 | $71K |
| bnp paribas financial markets | 6,809 | $24K |
| rhumbline advisers | 1,970 | $7K |
| gamma investing llc | 1,856 | $6K |
| osaic holdings, inc. | 68 | $240 |
| blue trust, inc. | 40 | $139 |
| farther finance advisors, llc | 22 | $80 |
| corecap advisors, llc | 21 | $73 |
Showing top 10 of 13 institutional holders of Alterity Therapeutics Limited. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Alterity Therapeutics Limited's pipeline?
Alterity Therapeutics Limited (ATHE) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Alterity Therapeutics Limited's next catalyst?
Alterity Therapeutics Limited's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: QDOLO" — expected September 1, 2040.
What is Alterity Therapeutics Limited's market capitalization?
Alterity Therapeutics Limited's market capitalization is approximately $93.2M.
Who is the CEO of Alterity Therapeutics Limited?
Dr. David A. Stamler M.D. is the chief executive officer of Alterity Therapeutics Limited (ATHE).
Get the full picture on Alterity Therapeutics Limited
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.